{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:39:24Z","timestamp":1791434364279,"version":"4.3.3"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To review the currently available evidence on transfer strategies from methadone to sublingual buprenorphine used in clinical trials and observational studies of medication for opioid use disorder treatment, and to consider whether any strategies yield better clinical outcomes than others.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Six medical and public health databases were searched for articles and conference abstracts. The Cochrane Central Register of Controlled Trials and the World Health Organization International Clinical Trials Registry Platform were used to identify unpublished trial results. Records were dually screened, and data were extracted and checked independently. Results were summarized qualitatively and, when possible, analyzed quantitatively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eighteen studies described transfer from methadone to buprenorphine. Transfer protocols were extremely varied. Most studies reported successful rates of transfer, even among studies involving transfer from high methadone doses, although lower pretransfer methadone dose was significantly associated with higher rate of successful transfer. Precipitated withdrawal was not reported frequently. A range of innovative approaches to transfer from methadone to buprenorphine remains untested.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Few studies have used designs that enable comparison of different approaches to transfer patients from methadone to buprenorphine. Most international clinical guidelines provide recommendations consistent with the available evidence. However, clinical guidelines should be perceived as providing \u201cguidance\u201d rather than \u201cprotocols,\u201d and clinicians and patients need to exercise judgment when attempting transfers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/adm.0000000000000855","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T22:17:34Z","timestamp":1619475454000},"page":"143-151","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Strategies for Transfer From Methadone to Buprenorphine for Treatment of Opioid Use Disorders and Associated Outcomes: A Systematic Review"],"prefix":"10.1097","volume":"16","author":[{"given":"Nicholas","family":"Lintzeris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baher","family":"Mankabady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rojas-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halle","family":"Amick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"issue":"(10159)","key":"R1-20250526","first-page":"1789","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study, 2017","volume":"392","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"(6)","key":"R7-20250526","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1465-3362.2009.00127.x","article-title":"Why do patients report transferring between methadone and buprenorphine?","volume":"28","author":"Winstock","year":"2009","journal-title":"Drug Alcohol Rev"},{"issue":"(3)","key":"R10-20250526","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF02246290","article-title":"Effects of buprenorphine and methadone in methadone-maintained subjects","volume":"119","author":"Walsh","year":"1995","journal-title":"Psychopharmacology"},{"issue":"(3)","key":"R11-20250526","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1517\/14740338.6.3.289","article-title":"Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology","volume":"6","author":"Ehret","year":"2007","journal-title":"Expert Opin Drug Saf"},{"issue":"(6)","key":"R12-20250526","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2007.01.040","article-title":"Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes","volume":"153","author":"Gupta","year":"2007","journal-title":"Am Heart J"},{"issue":"(7)","key":"R13-20250526","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.amjcard.2004.11.055","article-title":"Impact of methadone treatment on cardiac repolarization and conduction in opioid users","volume":"95","author":"Martell","year":"2005","journal-title":"Am J Cardiol"},{"issue":"(1)","key":"R14-20250526","doi-asserted-by":"crossref","first-page":"e0147852","DOI":"10.1371\/journal.pone.0147852","article-title":"Sexual dysfunction in heroin dependents: A comparison between methadone and buprenorphine maintenance treatment","volume":"11","author":"Yee","year":"2016","journal-title":"PLoS One"},{"issue":"(1)","key":"R15-20250526","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jsm.12352","article-title":"The prevalence of sexual dysfunction among male patients on methadone and buprenorphine treatments: A meta-analysis study","volume":"11","author":"Yee","year":"2014","journal-title":"J Sex Med"},{"issue":"(9)","key":"R16-20250526","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/hrt.2006.100180","article-title":"Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen","volume":"93","author":"Fanoe","year":"2007","journal-title":"Heart"},{"issue":"(22)","key":"R17-20250526","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.167.22.2469","article-title":"QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial","volume":"167","author":"Wedam","year":"2007","journal-title":"Arch Intern Med"},{"issue":"(1)","key":"R20-20250526","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1874473711205010052","article-title":"Buprenorphine-mediated transition from opioid agonist to antagonist treatment: State of the art and new perspectives","volume":"5","author":"Mannelli","year":"2012","journal-title":"Curr Drug Abuse Rev"},{"issue":"(1)","key":"R21-20250526","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/clpt.1984.150","article-title":"Electroencephalographic and behavioral correlates of buprenorphine administration","volume":"36","author":"Lukas","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"R22-20250526","article-title":"Detoxification and Induction onto Naltrexone","author":"Rosen","year":"1995","journal-title":"Buprenorphine: Combating Drug Abuse with a Unique Opioid"},{"issue":"(2)","key":"R23-20250526","first-page":"105","article-title":"A protocol to switch high-dose, methadone-maintained subjects to buprenorphine","volume":"6","author":"Levin","year":"1997","journal-title":"Am J Addict"},{"issue":"(Suppl 1)","key":"R24-20250526","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000052035","article-title":"Substitution with buprenorphine in methadone- and morphine sulfate-dependent patients. Preliminary results","volume":"4","author":"Bouchez","year":"1998","journal-title":"Eur Addict Res"},{"issue":"(1)","key":"R25-20250526","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0376-8716(03)00071-1","article-title":"Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions","volume":"71","author":"Breen","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"(4)","key":"R26-20250526","first-page":"365","article-title":"Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study","volume":"12","author":"Greenwald","year":"2003","journal-title":"Am J Addict"},{"issue":"(2)","key":"R27-20250526","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/13556210500123126","article-title":"Induction of patients with moderately severe methadone dependence onto buprenorphine","volume":"10","author":"Glasper","year":"2005","journal-title":"Addict Biol"},{"issue":"(11)","key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","article-title":"Buprenorphine retention in primary care","volume":"20","author":"Stein","year":"2005","journal-title":"J Gen Intern Med"},{"issue":"(1)","key":"R30-20250526","first-page":"49","article-title":"Induction from methadone to sublingual buprenorphine: A descriptive clinical trial in a methadone patients sample treated in therapeutic communities","volume":"10","author":"Gonzalez-Saiz","year":"2008","journal-title":"Trastor Adict"},{"issue":"(2)","key":"R31-20250526","first-page":"9","article-title":"Methadone-treated patients after switching to buprenorphine in residential therapeutic communities: An addiction-specific assessment of quality of life","volume":"11","author":"Gonzalez-Saiz","year":"2009","journal-title":"Heroin Addict Relat Clin Probl"},{"issue":"(2)","key":"R32-20250526","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/ADM.0b013e3181add3f5","article-title":"Transitioning stable methadone maintenance patients to buprenorphine maintenance","volume":"4","author":"Salsitz","year":"2010","journal-title":"J Addict Med"},{"issue":"(1)","key":"R33-20250526","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jsat.2010.04.001","article-title":"Factors associated with complicated buprenorphine inductions","volume":"39","author":"Whitley","year":"2010","journal-title":"J Subst Abuse Treat"},{"issue":"(5)","key":"R34-20250526","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1521-0391.2011.00159.x","article-title":"Transdermal buprenorphine to switch patients from higher dose methadone to buprenorphine without severe withdrawal symptoms","volume":"20","author":"Hess","year":"2011","journal-title":"Am J Addict"},{"issue":"(3)","key":"R35-20250526","first-page":"19","article-title":"Transfer to buprenorphine from daily doses of methadone greater than 30\u200amg - Initial review of transfers","volume":"15","author":"Conroy","year":"2013","journal-title":"Heroin Addict Relat Clin Probl"},{"issue":"(2)","key":"R36-20250526","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11469-014-9521-2","article-title":"High-dose methadone transfer to buprenorphine in outpatient settings","volume":"13","author":"Naumovski","year":"2015","journal-title":"Int J Ment Health Addict"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jsat.2015.05.004","article-title":"A retrospective evaluation of inpatient transfer from high-dose methadone to buprenorphine substitution therapy","volume":"57","author":"Oretti","year":"2015","journal-title":"J Subst Abuse Treat"},{"issue":"(3)","key":"R38-20250526","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/ADM.0000000000000396","article-title":"Transferring patients from methadone to buprenorphine: The feasibility and evaluation of practice guidelines","volume":"12","author":"Lintzeris","year":"2018","journal-title":"J Addict Med"},{"issue":"(10)","key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/phar.2313","article-title":"Transitioning hospitalized patients with opioid use disorder from methadone to buprenorphine without a period of opioid abstinence using a microdosing protocol","volume":"39","author":"Terasaki","year":"2019","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T20:08:13Z","timestamp":1748290093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0000000000000855","relation":{},"ISSN":["1932-0620","1935-3227"],"issn-type":[{"value":"1932-0620","type":"print"},{"value":"1935-3227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]}}}